Q2 2024

Filed Aug 8, 2024 · 10-Q · 39 days after period end · 0001730463-24-000093

Q2 2024 · 10-Q

Revenue

$0.00

no prior Q2 2023 on file

Net Income

-$58.27M

N/M vs Q2 2023

EPS Diluted

-$0.22

N/M vs Q2 2023

Operating Income-$58,929,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2020
Revenue	$0.00	—	—	$293.00K
Net Income	-$58.27M	-$45.55M	-$42.06M	-$32.05M
EPS Diluted	-$0.22	-$0.26	-$0.46	-$0.62

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR